JBJohn-Paul Bukowski

John-Paul Bukowski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John-Paul Bukowski has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Thrombin-mediated AutoRegulation of FVIII-mimetic antibodies enabling dynamic control of the hemostatic response

    by Vincent Muczynski, Angel Smith, Annalisa Baccaro, Dinusha Fernando, John-Paul Bukowski, Jenny Hazel McIntosh, Thibaud Sefiane, Olivier D. Christophe, Peter J Lenting, Kerry A. Chester, et al.

    Emicizumab has transformed hemophilia A (HA) management by enabling effective subcutaneous prophylaxis independent of inhibitor status. However, its constitutive activity and lack of sensitivity to anticoagulant feedback contribute to excessive thrombin generation under certain conditions, particularly when combined with bypassing agents, a liability increasingly recognized as a class effect of FVIII-mimetic antibodies. We engineered an "AutoRegulated" (AR) FVIII-mimetic antibody by integrating a short thrombin cleavable peptide sensitive to the proteolytic activity of thrombin in the hinge region of both emicizumab arms. Insertion of the peptide did not impair structural integrity and biological function with AR-emicizumab demonstrating EC50 values of FVIII-mimetic activity and correction of blood loss in HA mice comparable to the parental emicizumab. However, the presence of thrombin-mediated AR enabled thrombin-responsive proteolytic inactivation upon exposure to supra-physiological thrombin levels, whereas the parental emicizumab remained unaffected. The dynamic control provided by AR efficiently reduced the procoagulant effects induced by co-administration of activated Prothrombin Complex Concentrates (aPCC). In thrombin generation assays, AR-emicizumab significantly attenuated the excessive thrombin peak observed with emicizumab. Similarly, in vivo, the presence of thrombin-mediated AR prevented platelet consumptive coagulopathy and reduced the microvascular pulmonary thrombosis induced by the parental molecule without affecting the systemic levels of the therapeutic antibody. This on-demand self-limiting mechanism aligns therapeutic activity with local hemostatic needs, may offer a promising therapeutic approach for HA patients, while establishing a generalizable strategy to improve the safety profile of next-generation hemostatic biologics.

  • Open Access

    KDM3A catalyses the oxidation of acetyl-lysine to hydroxyacetyl-lysine on histone H3K9

    by Roman Belle, John-Paul Bukowski, Rachel Schiller, Ronald Cutler, Eidarus Salah, Robert S. Dawber, Anthony Tumber, Joanna Bonnici, Jessica D. Kindrick, Loane Serrano, et al.

    Histone modifications, including N ε -lysine acetylation and methylation, play critical roles in the regulation of eukaryotic transcription. The addition of acetyl and methyl groups and removal of acetyl groups to histones involve redox-neutral reactions. Demethylation is O 2 -dependent, as reported for reactions catalysed by the 2-oxoglutarate-dependent hypoxia-inducible factor (HIF) hydroxylases, one of which is structurally related to the Jumonji-C (JmjC) histone demethylases. We screened for substrates of the HIF-regulated JmjC lysine demethylase KDM3A and unexpectedly observed that purified recombinant KDM3A catalyses oxidation of the N ε -acetyl group of the Lys-9 of histone H3 (H3K9ac) giving an N ε -hydroxyacetylated product (H3K9acOH). Here we show that N ε -hydroxyacetyl-lysine is recognized by proteins known to bind to H3K9ac, including histone deacetylases and the YEATS domain-containing AF9. Studies employing an N ε -hydroxyacetyl-lysine selective antibody and mass spectrometry support the cellular relevance of N ε -hydroxyacetyl-lysine. Our combined biochemical and cellular results provide evidence for an unanticipated O 2 -mediated link between histone lysine N ε -acetylation and JmjC catalysis.